A lit­tle biotech's sec­ond crack at dry eye dis­ease comes up short. And this time there will be no ex­tra shot at suc­cess

You can add Au­rinia to the list of biotechs which fol­lowed mixed Phase II da­ta right over the late-stage cliff.

The biotech was ham­mered af­ter the mar­ket close when re­searchers an­nounced that their Phase II/III study of VOS for dry eye dis­ease had failed the pri­ma­ry end­point — an im­prove­ment. All three dos­es of the treat­ment flunked sta­tis­ti­cal sig­nif­i­cance, and now the biotech is killing the pro­gram off.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER